AACR: Merck pads case for less-frequent Keytruda dosing with new melanoma data

Merck's more convenient dosing schedule for Keytruda suffered an FDA rejection in February. (Merck)

After an FDA rejection, Merck is once again awaiting an approval decision on a more convenient dosing regimen for Keytruda. Now, it has some new data to support its case—and at a time when pandemic restrictions are complicating medical care, less-frequent dosing could be more important than ever.

In a study presented virtually at the American Association for Cancer Research annual meeting, a 400mg dose of the drug given every six weeks produced a similar response rate among melanoma patients as the 200mg dose given every three weeks, “indicating similarity of efficacy” between the regimens, researchers wrote in an abstract.

The safety profiles between the two dosing schedules were comparable, too, leading investigators to determine Keytruda given every six weeks “is a safe and effective dosing regimen and offers a more convenient option for patients and physicians.”

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

SPECIAL REPORT: The top 10 drugs by sales increase in 2020 - Keytruda

Thanks to pharmacokinetic modeling and simulation data unveiled at 2018’s American Society of Clinical Oncology (ASCO) annual meeting, the long-acting regimen already bears approvals in markets including the EU, Australia and New Zealand.

But the FDA had other ideas when it rejected Merck’s U.S. label update back in February. “Merck is reviewing the letter and will discuss next steps with the FDA,” the company said in a statement at the time.

That discussion apparently didn’t take too long, with the New Jersey drugmaker saying last week that it had resubmitted its dosing applications across all of Keytruda’s approved indications, both solo and in combinations.

SPECIAL REPORT: The top 20 pharma companies by 2019 revenue - Merck & Co.

“The oncology community is rapidly adapting cancer care during the COVID-19 pandemic in order to minimize exposure and keep cancer patients as safe as possible. Now more than ever, we believe it is critical to pursue a six-week dosing schedule for Keytruda,” Roy Baynes, M.D., Merck SVP and head of global clinical development, said in a statement.

“We appreciate FDA’s guidance during the resubmission period and look forward to working closely with the agency as they continue their review,” he added.

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity